The Rituximab used in the treatment of NHL patients may overcome BCL-2-mediated chemoresistance through the inhibition of IL-10, thus down-regulating BCL-2 expression (Park et al., 2009). This evidence concerns the gene IL10 and non-Hodgkin lymphoma.